<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16362714</article-id><article-id pub-id-type="pmc">3452072</article-id><article-id pub-id-type="publisher-id">237</article-id><article-id pub-id-type="doi">10.1007/s10194-005-0237-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Gawel</surname><given-names>M.</given-names></name><address><email>marek.gawel@sw.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aschoff</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Charlesworth</surname><given-names>B. R.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><collab>on behalf of the REALIZE Study Group</collab></contrib><aff id="Aff1"><label>1</label>Department of Medicine (Neurology), Sunnybrook and Women's Health
Sciences Centre, Suite 515, 60 Grosvenor Street, Toronto, Ontario M5S 1B6, Canada </aff><aff id="Aff2"><label>2</label>Department of Neurology, University of Ulm, Ulm, Germany </aff><aff id="Aff3"><label>3</label>Department of Neurology, University of Regensburg, Regensburg, Germany </aff><aff id="Aff4"><label>4</label>AstraZeneca, Macclesfield, UK </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>9</month><year>2005</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2005</year></pub-date><volume>6</volume><issue>5</issue><fpage>405</fpage><lpage>411</lpage><history><date date-type="received"><day>24</day><month>3</month><year>2005</year></date><date date-type="accepted"><day>7</day><month>7</month><year>2005</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag Italia 2005</copyright-statement></permissions><abstract id="Abs1"><p>In phase one of the
REALIZE study, zolmitriptan nasal
spray demonstrated a significant
headache response from 10 min
post&#x02013;dose and total symptom relief
from 30 min post&#x02013;dose. The objective
of phase two was to investigate
patients' dosing patterns, satisfaction
and preference following openlabel
treatment with the nasal spray.
Up to 3 attacks were treated. The
ITT population consisted of 851
patients. The median time from
onset of symptoms to treatment was
1 h 15 min (primary endpoint).
Most patients reported being satisfied
or very satisfied with
zolmitriptan nasal spray (75.7%).
Furthermore, the majority of
patients would be willing to use
zolmitriptan nasal spray in the
future (59.8%) and preferred
zolmitriptan nasal spray over previous
therapies (57.8%). Zolmitriptan
nasal spray was well tolerated.
Most patients were satisfied with
zolmitriptan nasal spray, were willing
to continue using it and preferred
it to previous therapies.</p></abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>Migraine</kwd><kwd>Zolmitriptan</kwd><kwd>Intranasal</kwd><kwd>Satisfaction</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Italia 2005</meta-value></custom-meta></custom-meta-group></article-meta></front></article>
